FDA partially lifts hold on Corautus Genetics' angina gene therapy trial
This article was originally published in Clinica
Executive Summary
The US FDA has partially lifted the clinical hold it had imposed on a trial of Corautus Genetics' gene-therapy product for angina, which is being developed in partnership with Boston Scientific.